Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Trial Timeline
Oct 28, 2021 → Jul 30, 2027
NCT ID
NCT05048797About Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed is a phase 3 stage product being developed by Daiichi Sankyo for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05048797. Target conditions include Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05048797 | Phase 3 | Active |
Competing Products
20 competing products in Locally Advanced or Metastatic Non-Small Cell Lung Cancer